Dr. Daniel Morgensztern
Claim this profileWashington University School of Medicine
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
23 reported clinical trials
42 drugs studied
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
EGFR positive
2Non-Small Cell Lung Cancer
Stage IV
PD-L1 positive
EGFR positive
Affiliated Hospitals
Clinical Trials Daniel Morgensztern is currently running
EP0031
for Cancer
The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies (NSCLC)
Recruiting1 award Phase 1 & 2
BI 764532
for Small Cell Lung Cancer
This study is open to adults with small cell lung cancer and other neuroendocrine cancers that are positive for the tumour marker delta-like 3 (DLL3). The study is in people with advanced cancer for whom previous treatment was not successful or no standard treatment exists. The purpose of this study is to find out the highest dose of BI 764532 and the best treatment schedule that people can tolerate. BI 764532 is an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. In this study, BI 764532 is given to people for the first time. That means no clinical data are available for BI 764532. Participants get BI 764532 either weekly or once every 3 weeks. If there is benefit for the participants and if they can tolerate it, the treatment is given for a maximum of 3 years. During this time, participants visit the study site about 20 times depending on the response to the treatment. Doctors record any unwanted effects and regularly check the general health of the participants.
Recruiting1 award Phase 110 criteria
More about Daniel Morgensztern
Clinical Trial Related4 years of experience running clinical trials · Led 23 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Daniel Morgensztern has experience with
- Pembrolizumab
- Atezolizumab
- Docetaxel
- Nivolumab
- Carboplatin
- Pemetrexed
Breakdown of trials Daniel Morgensztern has run
Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Morgensztern specialize in?
Daniel Morgensztern focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Daniel Morgensztern currently recruiting for clinical trials?
Yes, Daniel Morgensztern is currently recruiting for 6 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Daniel Morgensztern has studied deeply?
Yes, Daniel Morgensztern has studied treatments such as Pembrolizumab, Atezolizumab, Docetaxel.
What is the best way to schedule an appointment with Daniel Morgensztern?
Apply for one of the trials that Daniel Morgensztern is conducting.
What is the office address of Daniel Morgensztern?
The office of Daniel Morgensztern is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.